Abstract: The convergence of genomics and personalized medicine is redefining healthcare by enabling treatments tailored to individual genetic profiles. This article explores how genomic technologies, like whole-genome and exome sequencing, are revolutionizing diagnostics, disease risk prediction, and therapeutic strategies. It highlights the importance of pharmacogenomics and the P4 medicine framework (predictive, preventive, personalized, and participatory) as drivers of this transformation. The discussion also underscores the emergence of biobanks as indispensable tools that integrate biospecimens with longitudinal clinical data to support research and accelerate precision-based medical interventions globally.
Furthermore, the paper evaluates the operational and ethical dimensions of biobank development, such as biospecimen quality, sustainability, and regulatory compliance. It references national and international initiatives (e.g., UK Biobank, All of Us Research Program) that exemplify large-scale genomic infrastructure. Despite challenges like privacy concerns and knowledge gaps in both clinical and public domains, the study affirms the growing potential of genomics when backed by interdisciplinary collaboration and informed policy. Ultimately, the integration of genomic science and biobank networks offers a scalable pathway to equitable and individualized healthcare solutions.
Read the full research article here: ScienceDirect – Genomics & Biobanks in Personalized Medicine.